Study type

Study topic

Human medicinal product

Study topic, other

JAK inhibitors

Study type

Non-interventional study

Scope of the study

Drug utilisation

Data collection methods

Secondary use of data
Non-interventional study

Non-interventional study design

Cohort
Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(L01EJ) Janus-associated kinase (JAK) inhibitors
Janus-associated kinase (JAK) inhibitors
(L04AF) Janus-associated kinase (JAK) inhibitors
Janus-associated kinase (JAK) inhibitors
Population studied

Short description of the study population

The population level cohort study will include all subjects available in the selected databases from 1st January 2017 until the most recent data lock of their respective databases, with at least 365 days of data visibility.
The patient level cohort study will include all JAKi new users from the 1st January 2017 until the most recent data lock of their respective databases, with at least 365 days of data visibility.
Study design details

Study design

- Population level cohort study (objective 1)
- New user cohort study (objectives 2)

Main study objective

1. To estimate the incidence of new JAKi use, overall and for each individual JAKi ingredient.
2. To characterise new JAKi users and treatment for each individual JAKi ingredient, over all indications and stratified by indication.